Chandan Healthcare Limited reported a Profit After Tax (PAT) of ₹27.06 Cr for the financial year ended March 31, 2026, marking an increase of 22.04% from the previous year. Total income for FY26 stood at ₹280.67 Cr, a growth of 20.43% year-on-year, driven by network expansion and strategic partnerships. The company’s EBITDA for the year was ₹56.84 Cr, with margins expanding by 164 basis points to 20.25%. The audited financial results were approved by the Board of Directors on May 29, 2026.

For the quarter ended March 31, 2026, the company recorded a PAT of ₹6.92 Cr on a total income of ₹77.41 Cr. The statutory auditors issued an unmodified audit opinion on the financial results. During the period, the company recognised an exceptional item of ₹2.92 Cr for FY26 and ₹0.69 Cr for Q4 FY26 as a one-time non-recurring adjustment related to additional defined benefit obligations under the New Labour Codes.

Consolidated Financial Highlights

Operational Expansion

Chandan Healthcare expanded its network through new diagnostic centre launches in Mumbai, Kolkata, and Raipur. The company successfully launched more than 130 franchise centres during FY26 and targets the addition of over 1,000 franchise centres over the next two years. It also commenced online business initiatives to scale its digital healthcare platform.

The company strengthened its institutional presence by securing multiple long-term government healthcare projects. This includes Punjab government PPP projects involving installation of 1.5 Tesla MRI and 32-slice CT scan systems with an estimated project value of ₹800 Cr over 10 years, and a 10-year MRI project at the Civil Hospital in Rohtak, Haryana.

Management Commentary

Management highlighted that the total test count increased by 20.69% to 8.8 million tests, while patient count grew 12.81% to 2 million. The B2C segment grew 29%, while the B2B segment grew 50%. The company operates 72 diagnostic centres, including 19 comprehensive centres, 25 diagnostic centres, and 26 standalone labs. Three more central referral labs are under upgradation in Delhi, Raipur, and Bhopal.

Looking ahead, the company outlined six core pillars for growth, including a 'one district, one lab' initiative in Uttar Pradesh and Uttarakhand, exponential franchise scaling, and the launch of a genome lab in Lucknow. Management stated that while diagnostic business EBITDA is over 40%, consolidated margins are impacted by the pharmacy subsidiary, which has a 5% EBITDA margin. The company aims to maintain overall EBITDA between 30% and 35% during the expansion phase.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0B2N01016/e8506e68832f4be5.pdf

Chandan Healthcare Limited has reappointed its statutory and cost auditors for the financial year 2026-27 during a board meeting held on May 29, 2026. The Board approved the reappointment of M/s. Renu Agrawal & Co. as the statutory auditor and M/s. Rahul Jain & Associates as the cost auditor, each for a term of one year.

Statutory Auditor Details

M/s. Renu Agrawal & Co., a firm of Chartered Accountants holding FRN No. 018547C, has been reappointed to serve as the statutory auditor. The firm, located at Unit No. 302, Vipul Trade Centre, Sector 48, Sohna Road, Gurgaon-122018, offers services in audit and assurance, tax and regulatory, transaction advisory, and consulting.

Cost Auditor Details

The Board also reappointed M/s. Rahul Jain & Associates as the cost auditor for FY27. The firm, with FRN No. 101515, is a partnership firm of Cost Accountants based at 606, Signature Global Mall Vaishali Sector-3, Ghaziabad, UP – 201010. It specializes in Cost Audit, Costing Systems, and Cost Study and analysis.